CLINICAL TRIALS PROFILE FOR AMITIZA
✉ Email this page to a colleague
All Clinical Trials for amitiza
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00611442 ↗ | Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy | Completed | Takeda | N/A | 2007-10-01 | The primary outcomes of this procedure will be: 1. The cleanliness of the prep as measured by the Ottawa Scale (attachment a). Secondary outcomes will be: 1. Patient satisfaction with the prep measured by 5 point Likert scale (attachment b); 2. Procedure time; 3. The number and size of polyps detected on examination. |
| NCT00611442 ↗ | Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy | Completed | Brooke Army Medical Center | N/A | 2007-10-01 | The primary outcomes of this procedure will be: 1. The cleanliness of the prep as measured by the Ottawa Scale (attachment a). Secondary outcomes will be: 1. Patient satisfaction with the prep measured by 5 point Likert scale (attachment b); 2. Procedure time; 3. The number and size of polyps detected on examination. |
| NCT00620061 ↗ | Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone | Completed | Takeda | Phase 3 | 2007-12-01 | The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction. |
| NCT00620061 ↗ | Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone | Completed | Sucampo Pharma Americas, LLC | Phase 3 | 2007-12-01 | The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction. |
| NCT00620061 ↗ | Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone | Completed | Sucampo Pharmaceuticals, Inc. | Phase 3 | 2007-12-01 | The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction. |
| NCT00645801 ↗ | Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 4 | 2008-03-01 | The primary objective is to compare the effectiveness and tolerance of Amitiza® (lubiprostone) plus GoLYTELY® (polyethylene glycol-electrolyte solution) versus placebo and GoLYTELY ® (polyethylene glycol-electrolyte solution) as a bowel cleansing preparation for colonoscopy. |
| NCT00645801 ↗ | Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation | Completed | Henry Ford Health System | Phase 4 | 2008-03-01 | The primary objective is to compare the effectiveness and tolerance of Amitiza® (lubiprostone) plus GoLYTELY® (polyethylene glycol-electrolyte solution) versus placebo and GoLYTELY ® (polyethylene glycol-electrolyte solution) as a bowel cleansing preparation for colonoscopy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amitiza
Condition Name
Clinical Trial Locations for amitiza
Trials by Country
Clinical Trial Progress for amitiza
Clinical Trial Phase
Clinical Trial Sponsors for amitiza
Sponsor Name
